Cetuximab is a monoclonal antibody targeting the transmembrane receptor HER-1 (epidermal growth factor receptor, EGFR). In theory, inhibition of EGFR may influence tumor behavior since the receptor regulates many important tumor cell activities including tumor growth, angiogenesis, and inhibition of the apoptotic response to chemotherapy and radiotherapy. Available experimental data suggest that cetuximab may enhance the activity of chemotherapy and radiotherapy, reverse resistance to some anticancer drugs, and has itself anticancer activity. Early clinical data support the experimental results. This paper reviews the published findings on cetuximab in the treatment of advanced head and neck cancer and points out the future objectives of the clinical research on this drug.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape.
CNS Drugs
January 2025
New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032, USA.
The negative symptoms of schizophrenia include diminished emotional expression, avolition, alogia, anhedonia, and asociality, and due to their low responsiveness to available treatments, are a primary driver of functional disability in schizophrenia. This narrative review has the aim of providing a comprehensive overview of the current research developments in the treatment of negative symptoms in schizophrenia, and begins by introducing the concepts of primary, secondary, prominent, predominant, and broadly defined negative symptoms. We then compare and contrast commonly used research assessment scales for negative symptoms and review the evidence for the specific utility of widely available off-label and investigational treatments that have been studied for negative symptoms.
View Article and Find Full Text PDFMultifunctional electrospun nanofiber films of polyacrylonitrile and polyvinyl alcohol incorporating rhamnose and therapeutic agents for enhanced healing of infected burn wounds.
J Biomater Sci Polym Ed
January 2025
Department of Microbiology, University of Central Punjab, Lahore, Pakistan.
Infected burn wounds present significant clinical challenges due to delayed healing and risk of infection, necessitating advanced treatments that offer both antimicrobial and regenerative properties. This study aimed to develop and evaluate multifunctional electrospun nanofiber films incorporating rhamnose (as an angiogenic agent) and therapeutic agents, namely fluticasone, mupirocin, ciprofloxacin, and silver sulfadiazine, for the enhanced healing of infected burn wounds. Nanofibers containing rhamnose, polyacrylonitrile, polyvinyl alcohol and therapeutic agents were fabricated electrospinning.
View Article and Find Full Text PDFMechanisms and implications of antibiotic resistance in gram-positive bacterial strains.
Cell Mol Biol (Noisy-le-grand)
January 2025
Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Antibiotics play a fundamental role in protecting millions of lives from infectious diseases. However, an important drawback of antibiotic treatment is that each advancement was followed by the development of resistance. This is due to the fact that the majority of pathogenic bacteria are capable of becoming resistant to a number of antimicrobial agents.
View Article and Find Full Text PDF[Advances in the study of viruses inhibiting the production of advanced autophagy or interferon through Rubicon to achieve innate immune escape].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
January 2025
Department of Pathogen Biology and Immunology, Kunming Medical University, Kunming 650500, China. *Corresponding authors, E-mail:
The innate immune response is the first line of defense for the host against viral infections. Targeted degradation of pathogenic microorganisms through autophagy, in conjunction with pattern recognition receptors synergistically inducing the production of interferon (IFN), constitutes an important pathway for the body to resist viral infections. Rubicon, a Run domain Beclin 1-interacting and cysteine-rich domain protein, has an inhibitory effect on autophagy and IFN production.
View Article and Find Full Text PDF[Expression of BTLA/HVEM axis in hematological and prospects for immune target therapy].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
January 2025
Department of Hematology, Lanzhou University Second Hospital, Lanzhou 730000, China. *Corresponding authors, E-mail:
B and T lymphocyte attenuator (BTLA) is an inhibitory immune checkpoint, which typically interacts with herpesvirus entry mediator (HVEM) and plays a crucial role in regulating immune balance. BTLA interacts with its ligand HVEM in a cis manner on the surface of the same immune cell to maintain immune tolerance, while trans interactions on the surface of different immune cells mediate immunosuppressive effects. Dysregulation of the BTLA/HVEM axis can impair the functions of immune cells, particularly T lymphocytes, promoting immune escape of tumor cells and ultimately leading to tumor progression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!